Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Exploring CAR T-Cell Therapy for Aggressive Lymphomas Including DLBCL and CLL/SLL With Richter’s Transformation

10/18/2024

Craig Sauter , MD;

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...

At the 2024 Lymphoma, Leukemia &...

10/18/2024

Oncology

Videos

Targeted DNA Sequencing for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL

10/15/2024

Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...

Erin Wiedmeier-Nutor, MD,...

10/15/2024

Oncology

Conference Coverage

Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?

09/23/2024

At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.

At the 2024 SOHO meeting, Kerry...

09/23/2024

Oncology

Videos

Potential for Measurable Residual Disease as an End Point in Chronic Lymphocytic Leukemia Research

09/03/2024

Talal Hilal, MD, discusses an analysis on whether measurable residual disease can serve as a valuable end point in chronic lymphocytic leukemia clinical trials.

Talal Hilal, MD, discusses an...

09/03/2024

Oncology

Videos

Exciting Developments in Chronic Lymphocytic Leukemia Treatment Research

08/28/2024

Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.

Matthew Davids, MD, discusses...

08/28/2024

Oncology

Videos

Acalabrutinib-Based Regimens Demonstrate Long-Term Benefits Among Higher-Risk Patients With CLL

08/28/2024

Matthew Davids, MD, discusses results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk chronic lymphocytic leukemia in treatment-naive or...

Matthew Davids, MD, discusses...

08/28/2024

Oncology

Videos

Promising Developments in Chronic Lymphocytic Leukemia Treatment

08/20/2024

Talal Hilal, MD, discusses novel developments in the chronic lymphocytic leukemia treatment landscape, particularly a growing interest in utilizing measurable residual disease as an end point.

Talal Hilal, MD, discusses novel...

08/20/2024

Oncology

Videos

Exploring New Therapies on the Horizon for Patients With R/R Chronic Lymphocytic Leukemia

08/09/2024

Nirav R. Shah , MD;

Nirav Shah, MD, shares insights into the research on exciting new therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK degraders and cell therapies.

Nirav Shah, MD, shares insights...

08/09/2024

Oncology

Videos

How I Treat: An Older Patient With High-Risk CLL With Deletion 17p

07/15/2024

John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.

John Allan, MD, discusses the...

07/15/2024

Oncology

Conference Coverage

Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment

04/10/2024

Featuring John Allan, MD

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.

John Allan, MD, compares the use...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Chronic Lymphocytic Leukemia Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products